Clinical Insights Drive BiVictriX's Approach To Targeted Cancer Therapies
Listed On AIM
The UK biotech BiVictriX has completed a fundraising and listing on the UK’s AIM to support the development of antibody drug conjugates with “twin-antigen” targeting that could improve the selectivity of cancer therapeutics, with its lead candidate going up against acute myeloid leukemia.
You may also be interested in...
A new UK company, Poolbeg Pharma, has been set up to develop new anti-infectives in an efficient manner, and already has a repositioned MAP kinase inhibitor for the treatment of severe influenza ready for Phase II studies.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.